Last reviewed · How we verify
Hydromorphone hydrochloride low dose
At a glance
| Generic name | Hydromorphone hydrochloride low dose |
|---|---|
| Sponsor | Liquan Liang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Intrathecal Hydromorphone for Pediatric Idiopathic Scoliosis Repair (PHASE4)
- Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid (PHASE2)
- Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section (PHASE4)
- Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery (PHASE4)
- Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain (PHASE4)
- A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users (PHASE1)
- Perioperative Ketamine for Pain With Gastric Bypass (PHASE2)
- The Effect of Esketamine on Patients Undergoing Tumor Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydromorphone hydrochloride low dose CI brief — competitive landscape report
- Hydromorphone hydrochloride low dose updates RSS · CI watch RSS
- Liquan Liang portfolio CI